Hybrid inorganic-organic capsules for efficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection
| Parent link: | Scientific Reports Vol. 7.— 2017.— [102, 12 p.] |
|---|---|
| מחבר תאגידי: | |
| מחברים אחרים: | , , , , , , , |
| סיכום: | Title screen The implementation of RNAi technology into the clinical practice has been significantly postponing due to the issues regarding to the delivery of naked siRNA predominantly to target cells. Here we report the approach to enhance the efficiency of siRNA delivery by encapsulating the siRNA into new carrier systems which are obtained via the combination of widely used layer-by-layer technique and in situ modification by sol-gel chemistry. We used three types of siRNAs (NP-717, NP-1155 and NP-1496) in encapsulated form as new therapeutic agents against H1N1 influenza virus infection. By employing the hybrid microcontainers for the siRNA encapsulation we demonstrate the reduction of viral nucleoprotein (NP) level and inhibition of influenza virus production in infected cell lines (MDCK and A549). The obtained hybrid carriers based on assembled biodegradable polyelectrolytes and sol-gel coating possess several advantages such as a high cell uptake efficiency, low toxicity, efficient intracellular delivery of siRNAs and the protection of siRNAs from premature degradation before reaching the target cells. These findings underpin a great potential of versatile microencapsulation technology for the development of anti-viral RNAi delivery systems against influenza virus infection. |
| שפה: | אנגלית |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | http://dx.doi.org/10.1038/s41598-017-00200-0 |
| פורמט: | אלקטרוני Book Chapter |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=654915 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 654915 | ||
| 005 | 20250313143824.0 | ||
| 035 | |a (RuTPU)RU\TPU\network\20631 | ||
| 035 | |a RU\TPU\network\20395 | ||
| 090 | |a 654915 | ||
| 100 | |a 20170529d2017 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i | |
| 182 | 0 | |a b | |
| 200 | 1 | |a Hybrid inorganic-organic capsules for efficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection |f A. S. Timin [et al.] | |
| 203 | |a Text |c electronic | ||
| 300 | |a Title screen | ||
| 320 | |a [References: 56 tit.] | ||
| 330 | |a The implementation of RNAi technology into the clinical practice has been significantly postponing due to the issues regarding to the delivery of naked siRNA predominantly to target cells. Here we report the approach to enhance the efficiency of siRNA delivery by encapsulating the siRNA into new carrier systems which are obtained via the combination of widely used layer-by-layer technique and in situ modification by sol-gel chemistry. We used three types of siRNAs (NP-717, NP-1155 and NP-1496) in encapsulated form as new therapeutic agents against H1N1 influenza virus infection. By employing the hybrid microcontainers for the siRNA encapsulation we demonstrate the reduction of viral nucleoprotein (NP) level and inhibition of influenza virus production in infected cell lines (MDCK and A549). The obtained hybrid carriers based on assembled biodegradable polyelectrolytes and sol-gel coating possess several advantages such as a high cell uptake efficiency, low toxicity, efficient intracellular delivery of siRNAs and the protection of siRNAs from premature degradation before reaching the target cells. These findings underpin a great potential of versatile microencapsulation technology for the development of anti-viral RNAi delivery systems against influenza virus infection. | ||
| 461 | |t Scientific Reports | ||
| 463 | |t Vol. 7 |v [102, 12 p.] |d 2017 | ||
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a внутриклеточная доставка | |
| 610 | 1 | |a вирусные инфекции | |
| 610 | 1 | |a грипп | |
| 610 | 1 | |a H1N1 | |
| 701 | 1 | |a Timin |b A. S. |c Chemist |c Associate Scientist of Tomsk Polytechnic University |f 1989- |g Aleksandr Sergeevich |3 (RuTPU)RU\TPU\pers\37036 | |
| 701 | 1 | |a Muslimov |b A. R. | |
| 701 | 1 | |a Petrova |b A. V. | |
| 701 | 1 | |a Lepik |b K. V. | |
| 701 | 1 | |a Okilova |b M. V. | |
| 701 | 1 | |a Vasin |b A. V. | |
| 701 | 1 | |a Afanasyev |b B. V. | |
| 701 | 1 | |a Sukhorukov |b G. B. | |
| 712 | 0 | 2 | |a Национальный исследовательский Томский политехнический университет (ТПУ) |b Управление проректора по научной работе и инновациям (НРиИ) |b Центр RASA в Томске |b Лаборатория новых лекарственных форм (Лаб. НЛФ) |3 (RuTPU)RU\TPU\col\21677 |
| 801 | 2 | |a RU |b 63413507 |c 20170529 |g RCR | |
| 856 | 4 | |u http://dx.doi.org/10.1038/s41598-017-00200-0 | |
| 942 | |c CF | ||